CN103381187B - Houttuynoid E is preparing the application in medicament for resisting platelet aggregation - Google Patents
Houttuynoid E is preparing the application in medicament for resisting platelet aggregation Download PDFInfo
- Publication number
- CN103381187B CN103381187B CN201310254767.2A CN201310254767A CN103381187B CN 103381187 B CN103381187 B CN 103381187B CN 201310254767 A CN201310254767 A CN 201310254767A CN 103381187 B CN103381187 B CN 103381187B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- platelet aggregation
- medicament
- preparing
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VCNWTZPWIVDHGN-SLBJRTIWSA-N 2-[4,5-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=CC(O)=C(O)C=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 VCNWTZPWIVDHGN-SLBJRTIWSA-N 0.000 title claims abstract description 38
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000003146 anticoagulant agent Substances 0.000 abstract description 8
- 238000004220 aggregation Methods 0.000 abstract description 4
- 230000002776 aggregation Effects 0.000 abstract description 4
- 230000000702 anti-platelet effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 4
- 229960003009 clopidogrel Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to Houttuynoid E and prepare the application in medicament for resisting platelet aggregation.The Houttuynoid E that the present invention relates to belongs to first public preparing the purposes in medicament for resisting platelet aggregation, because framework types belongs to brand-new framework types, and its platelet aggregation inhibitory activity is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiplatelet aggregation, obviously there is significant progress simultaneously.
Description
Technical field
The present invention relates to the novelty teabag of Houttuynoid E, prepare the application in medicament for resisting platelet aggregation more specifically to this compound.
Background technology
Hematoblastic basic physiological function is sticked, assembles, discharges and secretory granule content (as ATP, 5-hydroxy tryptamine), and the platelet of quiescent condition changes states of physiologic function into and is hematoblastic activation.Can phospholipid surface be provided after platelet activation, promote the carrying out of blood coagulation, be formed and hold by fibrin the thrombosis that platelet forms.Therefore platelet is as a kind of visible component of blood, in the thrombosis of physiological hemostasis and pathology, plays a very important role.Clinical research shows, cardiovascular and cerebrovascular disease common is clinically as basic in hypertension, angina pectoris myocardial infarction, cerebral infarction and cerebral hemorrhage etc., all changes relevant with Abnormal Blood Rheology with platelet function.Antiplatelet drug conventional at present has heavier untoward reaction, therefore develops novel effective, that untoward reaction is little treatment very urgent with the medicine of prevention platelet aggregation.The present inventor studies by experiment, finds that Houttuynoid E has the effect of antiplatelet aggregation.
The compound H outtuynoid E that the present invention relates to is one and delivers (Chen in 2012, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids withNovel Skeletons from Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons fromHouttuynia cordata.Organic Letters 14 (7), 1772 – 1775.), the Houttuynoid E that the present invention relates to is belonged to first public preparing the purposes in medicament for resisting platelet aggregation, because framework types belongs to brand-new framework types, and its platelet aggregation inhibitory activity is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for antiplatelet aggregation, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides Houttuynoid E and prepare the application in medicament for resisting platelet aggregation.
The present invention, using aspirin and clopidogrel as positive drug, proves by experiment, and Houttuynoid E can significantly all significantly reduce by anticoagulant index, maintains an equal level with positive drug.
Described compound H outtuynoid E structure is as shown in formula I:
The Houttuynoid E that the present invention relates to belongs to first public preparing the purposes in medicament for resisting platelet aggregation, because framework types belongs to brand-new framework types, and its platelet aggregation inhibitory activity is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiplatelet aggregation, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound H outtuynoid E involved in the present invention is see document (Chen, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with NovelSkeletons from Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 g of compound Houttuynoid E, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention agent:
Get 20 g of compound Houttuynoid E, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Test example 1:Houttuynoid E is on the impact of rat platelet aggregation function
1. animal: cleaning grade Sprague-Dawley rat, male, body weight 200g-250g.
2. method and result
Animal is divided into blank group (waiting capacity solvent), aspirin group (ASA at random, 50mg/kg), clopidogrel group (7mg/kg), Houttuynoid E 0.625mg/kg group, Houttuynoid E 1.25mg/kg group, Houttuynoid E 2.5mg/kg group, often organize 8, gastric infusion, 1 time/d, continuous 5d.1h after last administration, with 3% pentobarbital sodium anesthetized rat (30mg/kg) respectively, take a blood sample through ventral aorta, with 3.8% liquor sodii citratis anticoagulant (blood: anticoagulant=9:1), 1000r/min, be separated platelet rich plasma (PRP), remainder is again with the centrifugal 15min of 3000r/min, be separated platelet poor plasma (PPP), by turbidimetry with ADP (252umol/L) for derivant, measure platelet aggregation rate in 5min with LBY-NJ blood pool instrument, and calculate platelet aggregation inhibition rate as follows, data are used
represent, carry out statistical procedures to organize a t inspection, the results are shown in Table 1.
Experimentally result is known, and each dosage group of Houttuynoid E can obviously suppress platelet aggregation in body, and drug effect and positive drug aspirin and clopidogrel maintain an equal level.
Table 1Houttuynoid E is to hematoblastic gathering suppression ratio
Compare with blank group:
*p<0.01
Conclusion: using aspirin and clopidogrel as positive drug, prove by experiment, Houttuynoid E can obvious anticoagulant, maintains an equal level, can be used for preparing medicament for resisting platelet aggregation with positive drug.
Claims (1)
1.Houttuynoid E is preparing the application in medicament for resisting platelet aggregation, described compound H outtuynoid E structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310254767.2A CN103381187B (en) | 2013-06-24 | 2013-06-24 | Houttuynoid E is preparing the application in medicament for resisting platelet aggregation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310254767.2A CN103381187B (en) | 2013-06-24 | 2013-06-24 | Houttuynoid E is preparing the application in medicament for resisting platelet aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103381187A CN103381187A (en) | 2013-11-06 |
| CN103381187B true CN103381187B (en) | 2015-08-19 |
Family
ID=49489254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310254767.2A Active CN103381187B (en) | 2013-06-24 | 2013-06-24 | Houttuynoid E is preparing the application in medicament for resisting platelet aggregation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103381187B (en) |
-
2013
- 2013-06-24 CN CN201310254767.2A patent/CN103381187B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103381187A (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3153510B1 (en) | Fused azines as chemokine cxcr4 receptor modulators and uses related thereto | |
| WO2017011517A1 (en) | Bis-amines, compositions, and uses related to cxcr4 inhibition | |
| CN103251610A (en) | Application of Aspeverin in preparation of anti-platelet aggregation medicines | |
| CN103381187B (en) | Houttuynoid E is preparing the application in medicament for resisting platelet aggregation | |
| CN103381175B (en) | Houttuynoid B is preparing the application in medicament for resisting platelet aggregation | |
| CN103356682B (en) | Houttuynoid D is preparing the application in medicament for resisting platelet aggregation | |
| CN103381170B (en) | Chukrasone A is preparing the application in medicament for resisting platelet aggregation | |
| CN103446120B (en) | Fluevirosines A is preparing the application in medicament for resisting platelet aggregation | |
| CN103356598B (en) | Application of Chukrasone B in preparing anti-platelet aggregation medicines | |
| CN105287498A (en) | Application of kendomycin C to prepare medicines resisting platelet aggregation | |
| CN105412090A (en) | Application of Daphenylline in preparing anti-platelet aggregation drugs | |
| CN103638015B (en) | Application of Manzamenone O in platelet aggregation inhibitor | |
| CN103462985B (en) | Application of spirooliganones B in preparation of medicine inhibiting platelet aggregation | |
| CN102872035B (en) | Application of Gypensapogenin A in medicaments against platelet aggregation | |
| CN103127153A (en) | Application of Gypensapogenin B in anti-platelet aggregation medicines | |
| CN102988349A (en) | Application of Aphanamixoid A for preparing platelet aggregation resistant medicine | |
| CN105412099A (en) | Application of Denudatine-type diterpenoid in preparation of medicine for resisting platelet aggregation | |
| CN105534975A (en) | Applications of herqueiazole in preparation of platelet aggregation inhibiting medicines | |
| CN105125562A (en) | Anti-platelet aggregation medicine and application thereof | |
| CN103356678A (en) | Application of Houttuynoid C in anti-platelet aggregation medicines | |
| CN103356679A (en) | Application of Houttuynoid A in preparation of anti-platelet aggregation medicines | |
| CN103127073A (en) | Application of Eryngiolide A in anti-platelet aggregation medicines | |
| CN103356562A (en) | Application of Sarcaboside B in preparation of medicines for resisting platelet aggregation | |
| CN103356583A (en) | Application of Sarcaboside A in preparing anti-platelet aggregation medicine | |
| CN103479648A (en) | Application of Kadcoccitones A to in preparation of anti-platelet aggregation medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171108 Address after: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space Patentee after: Chongqing San Mou science and Technology Development Co., Ltd. Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Patentee before: Ding Shengyu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201223 Address after: 224200 No.88 Gangcheng Avenue, Dongtai coastal economic zone, Yancheng City, Jiangsu Province Patentee after: Dongtai Haibin science and Technology Pioneer Park Management Co., Ltd Address before: 401120 office building of Chongqing advertising industrial park, No.18, shifucheng Avenue, Yubei District, Chongqing Patentee before: CHONGQING SUMARTE TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right |